Thank you to The New York Times for including PanCAN Chief Scientific and Medical Officer Dr. Anna Berkenblit’s perspective on what this approval means for patients and the pancreatic cancer community. 💊 www.nytimes.com/2026/08/26/science/…
nytimes.com
F.D.A. Approves the Drug Daraxonrasib That’s Poised to Transform Pancreatic Cancer
In a key clinical trial, patients who got the pill, daraxonrasib, lived twice as long as those who got chemotherapy.